Paclitaxel drives TREM2+ macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel - PubMed
3 months ago
- #TREM2
- #breast cancer
- #paclitaxel
- Nab-paclitaxel shows higher overall response rate and pathological complete response compared to paclitaxel in breast cancer patients.
- Paclitaxel increases TREM2+ macrophage infiltration in primary tumors, unlike nab-paclitaxel.
- Paclitaxel promotes lung metastasis in breast cancer models by recruiting TREM2+ macrophages.
- Mechanistically, paclitaxel enhances the ATF3-FGF2 axis in cancer cells, activating the EGR1-TREM2-EMT cytokine axis in macrophages.
- Targeting TREM2 with genetic ablation or antisense oligonucleotides suppresses paclitaxel-induced metastasis.
- Findings suggest TREM2 targeting could improve paclitaxel efficacy and reduce metastasis.